# Guiding Evidence Based Therapy Using Biomarker Intensified Treatment

Study · id `cardio:ct-nct01685840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01685840](<https://clinicaltrials.gov/study/NCT01685840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01685840

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 894 participants.

## Technical summary

Registry record NCT01685840. Randomized; no masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2016-09-20 (actual). Results posted on 2017-12-12.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 894 participants (enrolled count; ClinicalTrials.gov record NCT01685840, source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01685840, source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)
- Primary completion: 2016-09-20 (actual) (ClinicalTrials.gov record NCT01685840, source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)
- Completion: 2016-09-20 (actual) (ClinicalTrials.gov record NCT01685840, source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)
- Results first posted: 2017-12-12 (ClinicalTrials.gov record NCT01685840, source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT01685840, source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01685840-2017-12-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
- Acronym: GUIDE-IT
- Condition: Heart Failure
- Intervention (Other): Usual Care
- Intervention (Device): Biomarker-guided care NT-proBNP
- Lead sponsor: Duke University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Duke University (`cardio:org-duke-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (`cardio:pubmed-28829876`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure (`cardio:pubmed-30466512`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF (`cardio:pubmed-30611722`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score (`cardio:pubmed-30919549`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction (`cardio:pubmed-31466618`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial (`cardio:pubmed-32319999`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial (`cardio:pubmed-33754794`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction (`cardio:pubmed-33955231`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f6f399c09cb1a62d09793680084cf2026de8d20ecf6a4c0b494e1e409e1083c4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
